Study results for knee osteoarthritis show promise
Centrexion Therapeutics has announced “positive statistically significant topline results” from its Phase 2b study of CNTX-4975 for people with chronic moderate-to-severe pain from knee osteoarthritis, the company said.
The randomized, double-blind, placebo-controlled multicenter study looked at 165 people with chronic moderate-to-severe knee OA pain.
Researchers found treatment with a single injection of CNTX-4975 resulted in reduction of pain within days and the effect lasted at least six months. Twenty-two percent of patients had a 90% or greater reduction in knee pain, while more than two-thirds had a 50% or greater reduction in pain.
These results represent the largest clinically-relevant reductions in knee osteoarthritis pain that have been reported for any drug treatment, marketed or in development, the company said.
CNTX-4975 is a highly potent, ultrapure, synthetic form of injectable trans-capsaicin that works by selectively targeting the TRPV1 receptor to rapidly inactivate the local pain fibers transmitting signals to the brain, the company said.